loan

subject: Genzyme Corporation: Pharmavitae Profile 2016 Now Available At Reportsandreports [print this page]

Dallas, TX: ReportsandReports announce Genzyme Corporation: PharmaVitae Profile 2016 Market Research Report in its Store.

Browse complete Report at http://www.reportsandreports.com/market-reports/genzyme-corporation-pharmavitae-profile/

This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Genzyme's performance against key rivals in the prescription pharmaceutical sector

See how the company's core products of Cerezyme, Fabrazyme and Myozyme/Lumizyme will continue to act as the primary sales growth drivers

Assess the impact of the recent contamination of the Allston manufacturing facility on the company's performance through 2009

Table Of Contents

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly news update 3

Company introduction 3

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 8

Genzyme: PharmaVitae forecasts at a glance 9

Strategic insight 10

Genzyme success in ultra-niche markets 10

Combination of fast revenue growth and margin improvement leads to explosive profit growth 10

With the blockbuster model under threat, Genzyme's niche market strategy looks set to hold firm 11

High-risk blockbuster model out-dated? 11

Genzyme's niche market-targeting an alternative strategy 11

Greater economies of scale as rare genetic disorders franchise expands 12

Allston facility contamination impact Genzyme's 2009 performance 12

Genzyme's spread-risk strategy 13

The renal franchise is Genzyme's first major example of therapeutic diversification 13

Further therapeutic diversification, emerging player in oncology 14

Acquisition of Bayer products adds further strength to oncology offering 14

SWOT analysis 18

Strengths 18

Weaknesses 19

Opportunities 19

Threats 20

Table of Contents 21

Table of figures 23

Chapter 3 Quarterly news update 24

Product developments 24

Deals and alliances 25

Product deals 25

Technology deals 26

M&A activity 27

Company announcements 28

Future product milestones 29

Chapter 4 Company introduction 30

Key findings 30

Background 31

Key corporate developments 32

M&A history 33

Bone Care International 33

AnorMED acquisition 34

Mozobil: the catalyst 34

Bioenvision 35

Current corporate structure 35

Biotherapeutics 35

LSDs 36

The rarity of LSDs offers a significant niche opportunity 36

Genetics/diagnostics 37

Chapter 5 Company sales 38

Key findings 38

Prescription pharmaceutical sales and growth rate analysis, 2002-14 39

Product analysis 42

Product analysis, 2002-08 44

Product analysis, 2008-14 47

Therapy area analysis 51

Geographic analysis 55

Launch/core/expiry analysis 58

Explanation of launch/core/expiry analysis 58

Launch analysis, 2008-14 59

Core analysis, 2008-14 60

Expiry analysis, 2008-14 61

Launch/core/expiry configuration, 2008-14 62

Molecule type analysis 64

Externalization analysis 68

Chapter 6 Company financials 71

Key findings 71

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 72

Operating costs and profit analysis 74

Operating costs and profit analysis, 2002-08 75

Operating cost ratio and profit margin analysis, 2002-08 76

Operating cost ratio and profit margin analysis, 2008-14 77

Operating costs and profit analysis, 2008-14 78

Chapter 7 Key products and competitors 80

Key findings 80

Overview 81

Endocrine, metabolic and genetic disorders 82

Cerezyme 82

Overview 83

Sales forecast 84

A rare disorder, but significant sales growth 84

Allston manufacturing facility contamination impacts 2009 sales 84

Threat from Shire and Protalix toward the end of the forecast period 85

Long term threat from pharmacological chaperones, Shire/Amicus's Plicera 86

Myozyme/Lumizyme 87

Overview 87

Sales forecast 88

Genzyme's key growth driver 88

Development of Lumizyme expected to provide boost to sales 89

Fabrazyme 90

Overview 90

Sales forecast 91

Comprehensive exclusivity 91

Shire suffers blow with Replagal 91

Amicus could provide competition in the long term 92

Genitourinary 93

Renagel/Renvela 93

Overview 94

Sales forecast 95

Therapeutic diversification through M&A 95

Established product 95

Strong sales force and good safety... 95

...backed by the NKF 95

Competition does exist 96

Renvela developed in order to consolidate Genzyme's position as number one 96

Label expansion into CKD patients not on dialysis 96

Hectorol 97

Overview 97

Sales forecast 98

Product gained through acquisition 98

Used as a complimentary product 98

Competition from Amgen 98

Oncology 99

Mozobil 99

Overview 99

Sales forecast 100

Innovative therapy supporting Genzyme's exploration into oncology 100

Strong clinical trial data 100

Clolar 102

Overview 102

Sales forecast 103

Acquisition of Bioenvision provided Clolar and boosted Genzyme's oncology offering 103

While approval in AML will significantly broaden Clolar's label, increased economic constraints on healthcare systems may restrict its uptake 103

Price and further competition will impede growth 103

Central nervous system 105

Campath 105

Overview 105

Sales forecast 106

Phase II data show superior efficacy compared to Rebif 106

Safety concerns 107

Future market potential 107

Chapter 8 Appendix 109

R&D pipeline 109

References 110

Datamonitor reports 110

Abbreviations 110

About Datamonitor 112

About Datamonitor Healthcare 112

Datamonitor consulting 112

Disclaimer 114

List of Tables

Table 1: Genzyme - PharmaVitae forecasts at a glance 9

Table 2: Genzyme key product developments, 2009 24

Table 3: Genzyme product deals and alliances, 2009 25

Table 4: Genzyme technology deals and alliances, 2009 26

Table 5: Genzyme M&A activity, 2009 27

Table 6: Genzyme company announcements, 2009 28

Table 7: Genzyme future product milestones, 2009-11 29

Table 8: Genzyme's acquisition history (2000-2008) 33

Table 9: Genzyme product portfolio overview ($m), 2002-08 44

Table 10: Genzyme product portfolio overview ($m), 2008-14 47

Table 11: Genzyme prescription pharmaceutical sales by therapy area ($m), 2008-14 53

Table 12: Genzyme prescription pharmaceutical sales by geographic region ($m), 2008-14 56

Table 13: Genzyme launch portfolio overview ($m), 2008-14 59

Table 14: Genzyme core portfolio overview ($m), 2008-14 60

Table 15: Genzyme expiry portfolio overview ($m), 2008-14 61

Table 16: Genzyme prescription pharmaceutical sales by molecule type ($m), 2008-14 66

Table 17: Genzyme prescription pharmaceutical sales by source ($m), 2008-14 69

Table 18: Total Genzyme sales by business unit ($m), 2002-08 72

Table 19: Genzyme operating revenue/cost analysis ($m), 2002-08 75

Table 20: Genzyme operating cost ratio analysis (% of total revenues), 2002-08 76

Table 21: Genzyme operating cost ratio analysis (% of total revenues), 2008-14 77

Table 22: Genzyme operating revenue/cost analysis ($m), 2008-14 78

Table 23: Key products overview 81

Table 24: Cerezyme: overview 83

Table 25: Cerezyme: sales forecast ($m), 2008-14 84

Table 26: Myozyme/Lumizyme: overview 87

Table 27: Myozyme/Lumizyme: sales forecast ($m), 2008-14 88

Table 28: Fabrazyme: overview 90

Table 29: Fabrazyme: sales forecast ($m), 2008-14 91

Table 30: Renagel/Renvela: overview 94

Table 31: Renagel/Renvela: sales forecast ($m), 2008-14 95

Table 32: Hectorol: overview 97

Table 33: Hectorol: sales forecast ($m), 2008-14 98

Table 34: Mozobil: overview 99

Table 35: Mozobil: sales forecast ($m), 2008-14 100

Table 36: Clolar: overview 102

Table 37: Clolar: sales forecast ($m), 2008-14 103

Table 38: Campath: overview 105

Table 39: Campath (CNS): sales forecast ($m), 2008-14 106

Table 40: Genzyme's R&D pipeline (Phase I-registration) 109

List of Figures

Figure 1: The PharmaVitae Explorer 3

Figure 2: Genzyme prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 7

Figure 3: Genzyme's financial performance ($m), 2002-14 8

Figure 4: Genzyme's therapy area diversification, 2002-14 16

Figure 5: Genzyme SWOT analysis 18

Figure 6: Genzyme timeline 32

Figure 7: Current corporate structure 35

Figure 8: Genzyme prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 40

Figure 9: Key product sales ($m), 2002-14 43

Figure 10: Genzyme key sales growth drivers and resistors ($m), 2002-08 45

Figure 11: Genzyme key sales growth drivers and resistors ($m), 2008-14 48

Figure 12: Genzyme prescription pharmaceutical sales by therapy area ($m), 2002-14 52

Figure 13: Genzyme prescription pharmaceutical sales by geographic region ($m), 2002-14 55

Figure 14: Genzyme launch/core/expiry configuration ($m), 2008-14 62

Figure 15: Genzyme prescription pharmaceutical sales by molecule type ($m), 2002-14 65

Figure 16: Genzyme prescription pharmaceutical sales by source ($m), 2002-14 68

Figure 17: Genzyme operating revenue/cost analysis ($m), 2002-14 74

Browse all Healthcare Market Research Reports

Browse all Datamonitor Market Research Reports

Browse all Newly Published Market Research Reports

Related Reports:

Genzyme Corporation Market Share Analysis

Genzyme Corporation - SWOT Analysis

Mitsubishi Tanabe Pharma Corporation: PharmaVitae Profile

About Us:

Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Website: http://www.reportsandreports.com/

Blog: http://reportsnreports.wordpress.com/

Blog: http://reportsandreports.blogspot.com/

by: Ms.Sunita

welcome to loan (http://www.yloan.com/)